TWI347196B - Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier - Google Patents

Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier

Info

Publication number
TWI347196B
TWI347196B TW092134096A TW92134096A TWI347196B TW I347196 B TWI347196 B TW I347196B TW 092134096 A TW092134096 A TW 092134096A TW 92134096 A TW92134096 A TW 92134096A TW I347196 B TWI347196 B TW I347196B
Authority
TW
Taiwan
Prior art keywords
blood
substances
transport
brain barrier
density lipoprotein
Prior art date
Application number
TW092134096A
Other languages
English (en)
Other versions
TW200501999A (en
Inventor
Quattrone Alessandro
J Nelson Thomas
L Alkon Daniel
Original Assignee
Brni Neurosciences Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brni Neurosciences Inst filed Critical Brni Neurosciences Inst
Publication of TW200501999A publication Critical patent/TW200501999A/zh
Application granted granted Critical
Publication of TWI347196B publication Critical patent/TWI347196B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1275—Lipoproteins; Chylomicrons; Artificial HDL, LDL, VLDL, protein-free species thereof; Precursors thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
TW092134096A 2002-12-03 2003-12-03 Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier TWI347196B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43047602P 2002-12-03 2002-12-03

Publications (2)

Publication Number Publication Date
TW200501999A TW200501999A (en) 2005-01-16
TWI347196B true TWI347196B (en) 2011-08-21

Family

ID=32469478

Family Applications (1)

Application Number Title Priority Date Filing Date
TW092134096A TWI347196B (en) 2002-12-03 2003-12-03 Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier

Country Status (9)

Country Link
US (4) US7220833B2 (zh)
EP (1) EP1581186A2 (zh)
JP (2) JP4995423B2 (zh)
KR (2) KR101111477B1 (zh)
CN (2) CN100386068C (zh)
AU (1) AU2003302676A1 (zh)
CA (2) CA2791165C (zh)
TW (1) TWI347196B (zh)
WO (1) WO2004050062A2 (zh)

Families Citing this family (177)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1596828B1 (en) 2003-02-14 2011-12-28 Children's Hospital & Research Center at Oakland Lipophilic drug delivery vehicle and methods of use thereof
JP4786538B2 (ja) * 2003-10-01 2011-10-05 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド 親油性薬物送達ビヒクルおよびその使用方法
WO2007021735A2 (en) * 2005-08-10 2007-02-22 William Llewellyn Use of phospholipid arachidonic acids for increasing muscle mass in humans
US8252338B2 (en) * 2005-11-10 2012-08-28 The Regents Of The University Of California Synthetic LDL as targeted drug delivery vehicle
US20070122800A1 (en) * 2005-11-23 2007-05-31 Seoju Lee Methods for quantifying polymer attachment to a particle
JP5358187B2 (ja) 2005-12-15 2013-12-04 ジェネンテック， インコーポレイテッド ポリユビキチンを標的とする方法と組成物
TWI334784B (en) * 2006-04-14 2010-12-21 Buck Inst For Age Res Compositions and methods for suppression of amyloid plaque formation associated with neurodegenerative disorders
US20100150928A1 (en) 2006-05-04 2010-06-17 Geneetech, Inc. Methods and compositions relating to zpa polypeptides
RS56986B1 (sr) 2006-07-14 2018-05-31 Ac Immune Sa Humanizovana antitela na beta amiloid
CL2007002070A1 (es) 2006-07-14 2008-02-08 Ac Immune S A Genentech Inc Anticuerpo quimerico o humanizado, o fragmentos de ellos, que se adhieren especificamente a por lo menos un epitopo en la proteina beta-amiloide; molecula de acido nucleico que lo codifica; composicion que lo comprende; su uso para tratar enfermedade
EP2478903A1 (en) 2006-07-28 2012-07-25 Blanchette Rockefeller Neurosciences Institute Compositions comprising activators of PKC and inhibitors of PKC ubiquitination
DE102007006663A1 (de) * 2007-02-10 2008-08-21 Lts Lohmann Therapie-Systeme Ag Transport von Arzneistoffen über die Blut-Hirn-Schranke mittels Apolipoproteinen
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
US20090110739A1 (en) * 2007-05-15 2009-04-30 University Of North Texas Health Science Center At Forth Worth Targeted cancer chemotherapy using synthetic nanoparticles
BRPI0812478A2 (pt) 2007-06-12 2017-05-16 Ac Immune Sa anticorpo quimérico ou um fragmento do mesmo, ou anticorpo humanizado ou um fragmento do mesmo, molécula de ácido nucleico, vetor de expressão, célula, composição, métodos de prevenir, tratar ou aliviar os efeitos d euma ou mais doenças, de diagnosticar uma doença ou condição associada com amilóide em um indivíduo, de determinar a extensão de carga de placa amiloidogênica em um tecido e/ou fluidos corporais de um indivíduo, de desagregar fibras beta-amilóides pré-formadas e de prevenir degradação de neurônios induzidas por abeta, kit de teste, região variável de cadeia, e, linhagem de célula
NZ601843A (en) 2007-06-12 2014-01-31 Ac Immune Sa Monoclonal anti beta amyloid antibody
CN101998863B (zh) 2007-10-05 2015-09-16 基因技术公司 抗淀粉状蛋白β抗体在眼病中的用途
US20100297242A1 (en) * 2007-10-17 2010-11-25 Tae-Gwan Park Ldl-like cationic nanoparticles for deliverying nucleic acid gene, method for preparing thereof and method for deliverying nucleic acid gene using the same
US9550827B2 (en) 2007-10-19 2017-01-24 The Regents Of The University Of California Methods for ameliorating and preventing central nervous system inflammation
US7902147B2 (en) * 2007-11-05 2011-03-08 Duke University Chronic lymphocytic leukemia prognosis and treatment
TWI468417B (zh) 2007-11-30 2015-01-11 Genentech Inc 抗－ｖｅｇｆ抗體
EP2229411B1 (en) * 2007-12-12 2019-02-27 University Health Network High-density lipoprotein-like peptide-phospholipid scaffold ("hpps") nanoparticles
WO2009158678A1 (en) 2008-06-27 2009-12-30 Children's Hospital & Research Center At Oakland Lipophilic nucleic acid delivery vehicle and methods of use therefor
EP2318832B1 (en) 2008-07-15 2013-10-09 Academia Sinica Glycan arrays on ptfe-like aluminum coated glass slides and related methods
RU2536937C2 (ru) 2008-10-14 2014-12-27 Дженентек, Инк. Варианты иммуноглобулина и их применения
BRPI0919564A2 (pt) 2008-10-22 2019-09-24 Genentech Inc modulação da degeneração do axônio
US8734853B2 (en) 2008-11-17 2014-05-27 University Of North Texas Health Science Center At Fort Worth HDL particles for delivery of nucleic acids
BRPI0918204A2 (pt) 2008-12-23 2015-12-08 Genentech Inc igv variante composição farmaceutica e kit
CA2772715C (en) 2009-09-02 2019-03-26 Genentech, Inc. Mutant smoothened and methods of using the same
US20120328609A1 (en) 2009-10-22 2012-12-27 Genentech, Inc. Modulation of Axon Degeneration
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
ES2565208T3 (es) 2009-12-11 2016-04-01 F. Hoffmann-La Roche Ag Anticuerpos anti-VEGF-C y métodos de uso de los mismos
RU2559542C2 (ru) 2009-12-23 2015-08-10 Дженентек, Инк. Антитела против bv8 и их применение
TWI472348B (zh) 2009-12-30 2015-02-11 Ind Tech Res Inst 可通過血腦障壁之胜肽及包含此胜肽之傳輸系統
WO2011130332A1 (en) 2010-04-12 2011-10-20 Academia Sinica Glycan arrays for high throughput screening of viruses
CA2835489C (en) 2010-05-10 2018-03-06 Chi-Huey Wong Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
US9107890B2 (en) 2010-07-08 2015-08-18 Blanchette Rockefeller Neurosciences Institute PKC activators and anticoagulant in regimen for treating stroke
WO2012016173A2 (en) 2010-07-30 2012-02-02 Ac Immune S.A. Safe and functional humanized antibodies
US9289488B2 (en) 2010-08-12 2016-03-22 Ac Immune Sa Vaccine engineering
US9597312B2 (en) 2010-08-19 2017-03-21 Cognitive Research Enterprises, Inc. Treatment of cognitive disorders associated with abnormal dendritic spines using PKC activators
AU2011312205B2 (en) 2010-10-05 2015-08-13 Curis, Inc. Mutant smoothened and methods of using the same
JP6371526B2 (ja) 2010-10-07 2018-08-08 エーシー イミューン エス．エー． タウを認識するリン酸化部位特異的抗体
CN103189050B (zh) 2010-10-26 2017-09-29 Ac免疫有限公司 包含通过疏水部分修饰的肽的基于脂质体的构建体
CA2815840A1 (en) 2010-11-10 2012-05-18 Genentech, Inc. Methods and compositions for neural disease immunotherapy
TWI689314B (zh) 2010-11-30 2020-04-01 建南德克公司 低親和力血腦障壁受體抗體及其用途
US20140037552A1 (en) 2011-02-15 2014-02-06 Domokos Máthé Prussian blue based nanoparticle as multimodal imaging contrast material
EP2709670A4 (en) 2011-05-18 2015-01-21 Childrens Hosp Medical Center TARGETED ADMINISTRATION OF PROTEINS ACROSS THE HEMATO-ENCEPHALIC BARRIER
WO2013043864A1 (en) * 2011-09-23 2013-03-28 The Board Of Regents Of The University Of Texas System Compositions and methods related to endothelial targeting
EP2764022B9 (en) 2011-10-07 2017-02-22 AC Immune S.A. Phosphospecific antibodies recognising tau
EP2766028B1 (en) 2011-10-14 2017-08-16 F. Hoffmann-La Roche AG Peptide inhibitors of bace1
AR088827A1 (es) 2011-11-10 2014-07-10 Genentech Inc Metodos para tratar, diagnosticar, y monitorear la enfermedad de alzheimer
WO2013071281A1 (en) 2011-11-13 2013-05-16 Blanchette Rockefeller Neurosciences Institute Esters of dcpla and methods of treatment using the same
EP2776018B1 (en) 2011-11-13 2021-08-25 Cognitive Research Enterprises, Inc. Pkc activators and combinations thereof
US9644038B2 (en) 2011-12-21 2017-05-09 The Regents Of The University Of California Apolipoprotein nanodiscs with telodendrimer
SG11201406347TA (en) 2012-04-05 2014-11-27 Ac Immune Sa Humanized tau antibody
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
MX2014014234A (es) 2012-05-22 2015-05-07 Genentech Inc Benzamidas n-sustituidas y su uso en el tratamiento del dolor.
CA2871695A1 (en) 2012-05-22 2013-11-28 F. Hoffmann-La Roche Ag Substituted dipyridylamines and uses thereof
US8877236B2 (en) * 2012-06-28 2014-11-04 Universita Degli Studi Di Milano-Bicocca Liposomes active in-vivo on neurodegenerative diseases
KR101663436B1 (ko) 2012-07-06 2016-10-06 제넨테크, 인크. N-치환된 벤즈아미드 및 이의 사용 방법
AU2013306098A1 (en) 2012-08-18 2015-02-12 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
WO2014031762A1 (en) 2012-08-21 2014-02-27 Academia Sinica Benzocyclooctyne compounds and uses thereof
AR092684A1 (es) 2012-09-27 2015-04-29 Hoffmann La Roche Compuestos de sulfonamida sustituidos
AU2013204200B2 (en) 2012-10-11 2016-10-20 Brandeis University Treatment of amyotrophic lateral sclerosis
JP6426100B2 (ja) * 2012-10-19 2018-11-21 ヴェクト−オリュスＶｅｃｔ−Ｈｏｒｕｓ 薬物送達のための組成物及び方法
WO2014111496A1 (en) 2013-01-18 2014-07-24 F. Hoffmann-La Roche Ag 3-substituted pyrazoles and use as dlk inhibitors
KR20150131233A (ko) 2013-03-14 2015-11-24 제넨테크, 인크. 치환된 트리아졸로피리딘 및 이의 사용 방법
EP2970452A2 (en) 2013-03-15 2016-01-20 AC Immune S.A. Anti-tau antibodies and methods of use
CA2907912A1 (en) 2013-05-01 2014-11-06 F. Hoffmann-La Roche Ag C-linked heterocycloalkyl substituted pyrimidines and their uses
MY182082A (en) 2013-05-01 2021-01-18 Hoffmann La Roche Biheteroaryl compounds and uses thereof
US10086054B2 (en) 2013-06-26 2018-10-02 Academia Sinica RM2 antigens and use thereof
WO2014210564A1 (en) 2013-06-27 2014-12-31 Academia Sinica Glycan conjugates and use thereof
US9782476B2 (en) 2013-09-06 2017-10-10 Academia Sinica Human iNKT cell activation using glycolipids with altered glycosyl groups
RS58376B1 (sr) 2013-10-11 2019-04-30 Hoffmann La Roche Supstituisana heterociklična sulfonamidna jedinjenja korisna kao modulatori trpa1
WO2015058191A1 (en) 2013-10-18 2015-04-23 Blanchette Rockefeller Neurosciences Institute Halogenated esters of cyclopropanated unsaturated fatty acids for use in the treatment of neurodegenerative diseases
MX2016008110A (es) 2013-12-20 2016-08-19 Hoffmann La Roche Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos.
EP3094352B1 (en) 2014-01-16 2020-09-23 Academia Sinica Compositions and methods for treatment and detection of cancers
WO2016114819A1 (en) 2015-01-16 2016-07-21 Academia Sinica Compositions and methods for treatment and detection of cancers
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
ES2694857T3 (es) 2014-02-04 2018-12-27 Genentech, Inc. Smoothened mutante y métodos de uso de la misma
WO2015148975A1 (en) 2014-03-27 2015-10-01 Alkon Daniel L Compositions and methods to treat niemann-pick disease
WO2015148915A1 (en) 2014-03-27 2015-10-01 Academia Sinica Reactive labelling compounds and uses thereof
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
AU2015267045B2 (en) 2014-05-27 2021-02-25 Academia Sinica Anti-HER2 glycoantibodies and uses thereof
KR20220151036A (ko) 2014-05-27 2022-11-11 아카데미아 시니카 항-ｃｄ20 글리코항체 및 이의 용도
CA2950577A1 (en) 2014-05-27 2015-12-03 Academia Sinica Fucosidase from bacteroides and methods using the same
KR102494193B1 (ko) 2014-05-28 2023-01-31 아카데미아 시니카 항-ｔｎｆ-알파 글리코항체 및 이의 용도
US10005724B2 (en) 2014-07-07 2018-06-26 Genentech, Inc. Therapeutic compounds and methods of use thereof
EP3191500A4 (en) 2014-09-08 2018-04-11 Academia Sinica HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS
EP3221364B1 (en) 2014-11-19 2020-12-16 Genentech, Inc. Antibodies against bace1 and use thereof for neural disease immunotherapy
SI3221349T1 (sl) 2014-11-19 2021-02-26 Axon Neuroscience Se Humanizirano tau protitelo pri alzheimerjevi bolezni
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
US10149826B2 (en) * 2015-01-20 2018-12-11 Hyalo Technologies, LLC Method of preparing microspheres
KR102630294B1 (ko) 2015-01-24 2024-01-26 아카데미아 시니카 암 마커 및 이를 사용하는 방법
EP3248005B1 (en) 2015-01-24 2020-12-09 Academia Sinica Novel glycan conjugates and methods of use thereof
CN107614521B (zh) 2015-01-30 2022-02-08 台湾地区“中央研究院” 增进抗体功效的通用糖型组合物及方法
CN107636170A (zh) 2015-02-04 2018-01-26 健泰科生物技术公司 突变型Smoothened及其使用方法
WO2016142310A1 (en) 2015-03-09 2016-09-15 F. Hoffmann-La Roche Ag Tricyclic dlk inhibitors and uses thereof
WO2016183252A1 (en) 2015-05-11 2016-11-17 Alkon, Daniel, L. Treatment of neurodegenerative conditions using pkc activators after determining the presence of the apoe4 allele
KR20180008761A (ko) 2015-05-22 2018-01-24 제넨테크, 인크. 치환된 벤즈아미드 및 이의 이용 방법
US20160346221A1 (en) 2015-06-01 2016-12-01 Autotelic Llc Phospholipid-coated therapeutic agent nanoparticles and related methods
PE20221008A1 (es) 2015-06-24 2022-06-15 Hoffmann La Roche Anticuerpos anti-receptor de transferrina con afinidad disenada
CA2991655A1 (en) 2015-07-10 2017-01-19 Peptinovo Biopharma, Llc Formulations for improving the efficacy of hydrophobic drugs
US11207461B2 (en) 2015-07-30 2021-12-28 Anoop U. R Drug delivery system and method for controlled and continuous delivery of drugs into the brain by bypassing the blood brain barrier
JP2018526371A (ja) 2015-08-27 2018-09-13 ジェネンテック， インコーポレイテッド 治療化合物及びその使用方法
US10935544B2 (en) 2015-09-04 2021-03-02 Obi Pharma, Inc. Glycan arrays and method of use
WO2017048778A1 (en) * 2015-09-18 2017-03-23 Oklahoma Medical Research Foundation Method of transporting an agent across blood-brain, blood-cochlear or blood-cerebrospinal fluid barrier
US20180256537A1 (en) 2015-09-23 2018-09-13 Tapan K. Khan Methods for survival and rejuvenation of dermal fibroblasts using pkc activators
PE20181004A1 (es) 2015-10-02 2018-06-26 Hoffmann La Roche Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
WO2017062924A1 (en) 2015-10-08 2017-04-13 Alkon Daniel L Dosing regimens of pkc activators
EP3380466A1 (en) 2015-11-25 2018-10-03 Genentech, Inc. Substituted benzamides useful as sodium channel blockers
CN105483076B (zh) * 2015-12-23 2019-01-25 中国科学院生物物理研究所 一种脂肪体的制备方法及其应用
CN109071625A (zh) 2016-02-04 2018-12-21 柯瑞斯公司 平滑化突变体和其使用方法
WO2017156192A1 (en) 2016-03-08 2017-09-14 Academia Sinica Methods for modular synthesis of n-glycans and arrays thereof
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
BR112018070097A2 (pt) 2016-03-29 2019-02-12 Obi Pharma, Inc. anticorpo, hibridoma, composição farmacêutica, método para tratar câncer em um indivíduo, método para inibir a proliferação de células cancerígenas, método para diagnosticar o câncer em um indivíduo, método para tratar um paciente humano, método para fazer imagens de um indivíduo, conjugado de fármaco-anticorpo (adc), método para tratar câncer, anticorpo biespecífico e método para preparar uma população de anticorpos homogêneos
EP3436432B1 (en) 2016-03-30 2021-01-27 Genentech, Inc. Substituted benzamides and methods of use thereof
EP3445395A4 (en) 2016-04-22 2019-12-25 OBI Pharma, Inc. ANTI-CANCER IMMUNOTHERAPY BY IMMUNO-ACTIVATION OR IMMUNOMODULATION THROUGH GLOBO SERIES ANTIGENS
CN109476640B (zh) 2016-07-20 2022-02-25 豪夫迈·罗氏有限公司 双环脯氨酸化合物
EP3487849A1 (en) 2016-07-20 2019-05-29 H. Hoffnabb-La Roche Ag Sulfonylcycloalkyl carboxamide compounds as trpa1 modulators
TWI752988B (zh) 2016-07-27 2022-01-21 台灣浩鼎生技股份有限公司 免疫性/治療性聚醣組合物及其用途
TWI786054B (zh) 2016-07-29 2022-12-11 台灣浩鼎生技股份有限公司 人類抗體、醫藥組合物、及其方法
EP3497093B1 (en) 2016-08-12 2021-09-15 F. Hoffmann-La Roche AG Sulfonyl pyridyl trp inhibitors
CN109963868B (zh) 2016-08-22 2023-11-14 醣基生医股份有限公司 抗体、结合片段及使用方法
EP3518901A1 (en) * 2016-09-30 2019-08-07 Eriochem USA, LLC Apo-e modified lipid nanoparticles for drug delivery to targeted tissues and therapeutic methods
EP3526219B1 (en) 2016-10-17 2021-12-15 F. Hoffmann-La Roche AG Bicyclic pyridone lactams and methods of use thereof
AU2017361549B2 (en) 2016-11-21 2023-12-21 Obi Pharma, Inc. Conjugated biological molecules, pharmaceutical compositions and methods
WO2018096159A1 (en) 2016-11-28 2018-05-31 F. Hoffmann-La Roche Ag Oxadiazolones as transient receptor potential channel inhibitors
TW201831478A (zh) 2016-12-02 2018-09-01 瑞士商赫孚孟拉羅股份公司 雙環醯胺化合物及其使用方法
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
JP7178357B2 (ja) 2017-03-07 2022-11-25 エフ．ホフマン－ラ ロシュ アーゲー オキサジアゾール一過性受容器電位チャネル阻害剤
EP3601273B1 (en) 2017-03-24 2021-12-01 Genentech, Inc. 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors
CN110914271A (zh) 2017-07-14 2020-03-24 豪夫迈·罗氏有限公司 二环酮化合物及其使用方法
AU2018348930A1 (en) 2017-10-11 2020-03-26 F. Hoffmann-La Roche Ag Bicyclic compounds for use as RIP 1 kinase inhibitors
AU2018358883A1 (en) 2017-10-30 2020-04-23 F. Hoffmann-La Roche Ag Method for in vivo generation of multispecific antibodies from monospecific antibodies
EP3704097B1 (en) 2017-10-31 2023-10-25 F. Hoffmann-La Roche AG Bicyclic sulfones and sulfoxides and methods of use thereof
US11649246B2 (en) 2017-11-30 2023-05-16 Hanmi Pharm. Co., Ltd. Salts of 4-amino-N-(l-((3-chloro-2-fluorophenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-D]pyrimidine-7-carboxamide, and crystalline forms thereof
AR114585A1 (es) 2018-02-20 2020-09-23 Hoffmann La Roche Proceso para preparar compuestos antagonistas de canales potenciales transitorios del receptor de 1-arilsulfonil-pirrolidin-2-carboxamida y formas cristalinas de los mismos
EP3759098A1 (en) 2018-02-26 2021-01-06 Genentech, Inc. Pyridine-sulfonamide compounds and their use against pain and related conditions
US10710994B2 (en) 2018-03-19 2020-07-14 Genentech, Inc. Oxadiazole transient receptor potential channel inhibitors
SG11202008098TA (en) 2018-03-28 2020-10-29 Axon Neuroscience Se Antibody-based methods of detecting and treating alzheimer's disease
JP2021519788A (ja) 2018-03-30 2021-08-12 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ナトリウムチャネル阻害剤としての縮合環ヒドロピリド化合物
US20190307892A1 (en) * 2018-04-04 2019-10-10 Eriochem Usa, Llc Targeted drug delivery and therapeutic methods using apo-e modified lipid nanoparticles
CN112074519A (zh) 2018-04-20 2020-12-11 豪夫迈·罗氏有限公司 作为rip1激酶抑制剂用于治疗e.g.肠易激综合征（ibs）的n-[4-氧代-2,3-二氢-1,5-苯并氧氮杂-3-基]-5,6-二氢-4h-吡咯并[1,2-b]吡唑-2-甲酰胺衍生物和有关化合物
TW202003490A (zh) 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
CN110604821A (zh) * 2018-06-14 2019-12-24 复旦大学 一种淀粉样蛋白β短肽介导的脑靶向递送系统
TW202035444A (zh) 2018-06-27 2020-10-01 台灣浩鼎生技股份有限公司 用於糖蛋白工程的糖苷合成酶變體及其使用方法
CN108685875B (zh) * 2018-07-30 2020-11-03 中国药科大学 一种抗阿尔兹海默症的天然纳米粒-药物组合物及其制备方法和应用
US11517685B2 (en) 2019-01-18 2022-12-06 Qnovia, Inc. Electronic device for producing an aerosol for inhalation by a person
US11690963B2 (en) 2018-08-22 2023-07-04 Qnovia, Inc. Electronic device for producing an aerosol for inhalation by a person
EP3847154A1 (en) 2018-09-03 2021-07-14 F. Hoffmann-La Roche AG Carboxamide and sulfonamide derivatives useful as tead modulators
EP3863453A4 (en) * 2018-10-18 2022-11-23 Qnovia, Inc. ELECTRONIC DEVICE FOR PRODUCING AN AEROSOL INTENDED TO BE INHALED BY A PERSON
CN109323910B (zh) * 2018-12-03 2021-01-08 徐州市中心医院 一种高纯度低密度脂蛋白的制备方法
EP3908586B1 (en) 2019-01-11 2022-12-21 F. Hoffmann-La Roche AG Bicyclic pyrrolotriazolr ketone compounds and methods of use thereof
CN114728905A (zh) 2019-11-13 2022-07-08 基因泰克公司 治疗性化合物及使用方法
CN115151562A (zh) 2019-12-04 2022-10-04 Ac免疫有限公司 用于治疗和诊断的新分子
CN111150834A (zh) * 2020-01-06 2020-05-15 吉林大学 一种载脂蛋白e与盐霉素复合纳米粒及制备方法和应用
WO2021186079A1 (en) * 2020-03-20 2021-09-23 Heidelberg University Colloidal carrier systems for transfer of agents to a desired site of action
US11787775B2 (en) 2020-07-24 2023-10-17 Genentech, Inc. Therapeutic compounds and methods of use
US20230322908A1 (en) 2020-08-14 2023-10-12 Ac Immune Sa Humanized Anti-TDP-43 Binding Molecules and Uses Thereof
MX2023003759A (es) 2020-10-02 2023-04-24 Genentech Inc Proceso para la preparacion de compuestos de biheteroarilo y formas cristalinas de estos.
US20230365618A1 (en) * 2020-10-12 2023-11-16 Durect Corporation Crystalline thiocholesterol
EP4229082A1 (en) 2020-10-16 2023-08-23 AC Immune SA Antibodies binding to alpha-synuclein for therapy and diagnosis
EP4358936A1 (en) * 2021-06-22 2024-05-01 Bio-TRIP B.V. Nucleic acid containing nanoparticles
WO2023028077A1 (en) 2021-08-24 2023-03-02 Genentech, Inc. Sodium channel inhibitors and methods of designing same
WO2023028056A1 (en) 2021-08-24 2023-03-02 Genentech, Inc. 3-amino piperidyl sodium channel inhibitors
TW202332429A (zh) 2021-11-24 2023-08-16 美商建南德克公司 治療性化合物及其使用方法
US20230203062A1 (en) 2021-11-24 2023-06-29 Genentech, Inc. Therapeutic compounds and methods of use
WO2023156549A1 (en) 2022-02-16 2023-08-24 Ac Immune Sa Humanized anti-tdp-43 binding molecules and uses thereof
US11951177B2 (en) 2022-03-23 2024-04-09 Nanovation Therapeutics Inc. High sterol-containing lipid nanoparticles
WO2023194565A1 (en) 2022-04-08 2023-10-12 Ac Immune Sa Anti-tdp-43 binding molecules
WO2023233042A1 (en) * 2022-06-03 2023-12-07 Bio-Trip B.V. Polyvalent molecule based lipid nanoparticles for nucleic acid delivery
KR20230171408A (ko) * 2022-06-13 2023-12-20 (주) 멥스젠 아포지단백질을 포함하는 하이브리드 나노입자의 합성 방법
WO2024079662A1 (en) 2022-10-11 2024-04-18 Meiragtx Uk Ii Limited Upf1 expression constructs

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3828106A (en) * 1972-01-03 1974-08-06 Biolog Concepts Inc Novel oral pharmaceutical dosage form
EP0238645A1 (en) 1985-10-03 1987-09-30 Biotechnology Research Partners, Ltd. Novel lipoprotein-based drug-delivery systems
FR2609399A1 (fr) 1987-01-13 1988-07-15 Ire Celltarg Sa Procede d'incorporation d'un ou plusieurs principes actifs lipophiles dans des lipoproteines, lipoproteines obtenues et composition pharmaceutique les contenant
FR2664500B1 (fr) * 1990-07-13 1994-10-28 Lille Ii Universite Droit Sant Procede de preparation d'une lipoproteine modifiee par incorporation d'une substance active lipophile, lipoproteine modifiee ainsi obtenue et composition pharmaceutique ou cosmetique la contenant.
FR2677272B1 (fr) 1991-06-05 1995-03-03 Biovecteurs As Vecteur particulaire a tropisme selectif, procede de preparation et composition pharmaceutique.
BR9201168A (pt) * 1992-04-02 1994-04-12 Zerbini E J Fundacao Microemulsoes usadas como velculo para carregar quimioterapicos as celulas neoplasicas
US5851510A (en) * 1994-05-16 1998-12-22 The Board Of Regents Of The University Of Michigan Hepatocyte-selective oil-in-water emulsion
GB9620153D0 (en) * 1996-09-27 1996-11-13 Univ Strathclyde Non-naturally occurring lipoprotein particle
EP0964690B1 (en) * 1996-10-15 2003-07-09 The Liposome Company, Inc. Peptide-lipid conjugates, liposomes and liposomal drug delivery
US6261537B1 (en) * 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
SE9702776D0 (sv) 1997-07-22 1997-07-22 Pharmacia & Upjohn Ab Method of preparing pharmaceutical compositions
DE19745950A1 (de) * 1997-10-17 1999-04-22 Dds Drug Delivery Service Ges Arzneistoffträgerpartikel für die gewebespezifische Arzneistoffapplikation
KR100314496B1 (ko) * 1998-05-28 2001-11-22 윤동진 항혈전성이 있는 헤파린 유도체, 그의 제조방법 및 용도
US6703381B1 (en) * 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
EP1880736A1 (en) * 1999-04-23 2008-01-23 Alza Corporation Releasable linkage and composition containing same

Also Published As

Publication number Publication date
US7220833B2 (en) 2007-05-22
AU2003302676A1 (en) 2004-06-23
JP5587352B2 (ja) 2014-09-10
EP1581186A2 (en) 2005-10-05
JP2012131799A (ja) 2012-07-12
CA2507762C (en) 2013-02-05
KR101111477B1 (ko) 2012-02-23
US20040204354A1 (en) 2004-10-14
JP4995423B2 (ja) 2012-08-08
CN101284136A (zh) 2008-10-15
KR101186210B1 (ko) 2012-10-08
TW200501999A (en) 2005-01-16
US20070264351A1 (en) 2007-11-15
JP2006516539A (ja) 2006-07-06
US7576055B2 (en) 2009-08-18
WO2004050062A3 (en) 2004-12-29
CA2791165A1 (en) 2004-06-17
CA2507762A1 (en) 2004-06-17
AU2003302676A8 (en) 2004-06-23
KR20110086775A (ko) 2011-07-29
CA2791165C (en) 2015-02-24
US7514402B2 (en) 2009-04-07
US7682627B2 (en) 2010-03-23
US20070134313A1 (en) 2007-06-14
US20070292413A1 (en) 2007-12-20
CN100386068C (zh) 2008-05-07
KR20050084163A (ko) 2005-08-26
CN1717223A (zh) 2006-01-04
WO2004050062A2 (en) 2004-06-17

Similar Documents

Publication Publication Date Title
TWI347196B (en) Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier
IL166217A0 (en) Combination of drugs for the treatment of neoplasms
AU2003244650A8 (en) Medicinal compounds
MY145338A (en) Stabilized polyethylene material
HK1072588A1 (en) Transport system
AU2003251904A1 (en) Combinations of drugs for the treatment of neoplasms
EP1617847A4 (en) PROCEDURE FOR THE CONTROLLED DISPOSAL OF PHARMACOLOGICAL ACTIVE SUBSTANCES
EP1484061A4 (en) DRUGS CONTAINING COMPOUNDS OF THE RIBOFLAVIN TYPE
IL169107A0 (en) Device for coular delivery of active principles by the transpalphebral route
AU2003291642A8 (en) Pyrazoloazepine compounds as pharmaceutical agents
GB0315058D0 (en) Patient transportation apparatus
EP1630317A4 (en) ANTI-DEVIATION STRUCTURE FOR A CORNER
AU2003302320A8 (en) Seterocyclic quinones as pharmaceutical agents
GB2388143B (en) Transport system
HUP0302494A3 (en) Means of transport for long rails
GB0201097D0 (en) Advanced transport system
AU155083S (en) Pharmaceutical packaging
GB2402121B (en) Transport apparatus
AU2003231332A1 (en) Container for the transport of livestock
GB0401743D0 (en) Transport system
GB0219893D0 (en) Pharmaceutically active compounds
AU2002246275A1 (en) Transport triggered microprocessor architecture
PL113535U1 (en) Transport set
GB0202477D0 (en) Magnetract transport system
GB2426629B (en) Packaging structure for imaging detectors

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees